Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree

The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.

Sales & Earnings Cancer Commercial

Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research

The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.

Sales & Earnings Business Strategies Leadership

Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns

Committee overwhelmingly supports approval for treatment-resistant depression but warns that pricing and combination therapy indication could hinder patient access. Esketamine’s risks of sedation and dissociative effects, and its abuse potential, will necessitate a strict risk management strategy.

Advisory Committees Drug Review Neurology
Advertisement


 Recent Tweets from Scrip


Pulse Of The Industry 2018: How Medtechs Will Create Value In The New Health Ecosystem

In the 12th edition of EY’s medtech report, The Pulse of the Industry, they examine the annual performance of the medical device industry in the context of the technological advances and rising customer expectations associated with the Fourth Industrial Revolution. To thrive in this transformative age, medtechs must adapt their business models to meet the increased expectations of consumers and other health care stakeholders.

Read more

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop Now

 

Commercial Explore this Topic

Set Alert for Commercial

A Trough Year For Teva, With A Turning Point Targeted For 2020

As the company's turnaround plan matures, 2019 will remain a year of cost-cutting and focus as it looks to pay down debt and stabilize its financials. "We'll be focused on optimizing our own business rather than adding new businesses," CEO Schultz said.

Sales & Earnings Generic Drugs Business Strategies

Sun’s Ilumya Gnaws At US Psoriasis Market

Around 800 physicians have prescribed Sun’s Ilumya, giving it some early traction in the competitive US psoriasis market. The Indian firm is striving to push harder and will also take a call on pursuing additional indications for the product.

Commercial Strategy Sales & Earnings

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.

Business Strategies Commercial

AZ China Growth Pops Again But Clouds Loom

Lying underneath AstraZeneca’s stellar quarter were the growth engines of emerging markets and China, where novel drugs, especially in oncology, delivered. But mounting pricing pressures and a massive new centralized bidding process are clouds on the horizon.

Commercial Business Strategies

Bruised Roche Wins Another UK Perjeta Round With Price Cut

In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.

United Kingdom Cancer

Glenmark Spins Out Innovation With New US Base

Glenmark’s innovation business will now be housed in a spin-out arm, based in the US, where the Indian parent believes the ecosystem is more conducive to cutting-edge R&D. The new structure could also potentially provide new opportunities to unlock value for the parent company.
Commercial Strategy

Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates

Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter. 

Deals Financing

Analysts Upbeat On Aurobindo After Strong Earnings

Analysts are enthusiastic about the US earnings prospects of leading Indian generic firm Aurobindo after the company reported a nearly 20% jump in consolidated net profit for the third quarter, and declared it would focus on digesting its acquisitions.

India Commercial

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access

Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.

China Rare Diseases Market Access

AZ And Ipsen Outline Brexit Contingency Plans

With the UK no nearer to deciding how hard or soft its exit from the EU will be on March 29, AstraZeneca and Ipsen have given updates on their efforts to cope with the chaos that could ensue on the medicines supply front.

United Kingdom Brexit

J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies

Part 3: Scrip spoke with companies working on cell and gene therapies and novel approaches to neurological diseases during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.

Business Strategies Research and Development Strategies

Interview: Altan Eyes Opportunities In US Pain Market

The Irish specialty pharma has made its first filing in the US with an infusion of acetaminophen that Altan hopes will break the monopoly of Mallinckrodt's Ofirmev.

Neurology Generic Drugs

Research & Development Explore this Topic

Set Alert for Research & Development

Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD

The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.

 

Neurology Clinical Trials Research & Development

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?

Cancer Gynecology & Urology

Affinivax’s MAPS Vaccine Technology Reaches Clinic In Under Five Years

Funded entirely by grants and partnerships to date, Affinivax’s pneumococcal vaccine candidate has begun a Phase I/II study less than five year’s after the biotech’s founding. Firm thinks its technology may eventually apply to immuno-oncology as well.

Vaccines Clinical Trials

In NASH, Gilead Swung For The Fences And Struck Out Again

Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.

Clinical Trials Research & Development
UsernamePublicRestriction

Register

Advertisement